You may qualify and be compensated up to $6,000 if you meet the following requirements:
Study design: The study will last up to 7 weeks (from screening to the end of the study visit), with:
Access the Pre-Screening Questionnaire here.
Next check-in dates: click here for the study calendars.
Study objective: The study aims to assess if three different commercial dosage strengths of Palovarotene (2.5 mg, 5 mg, and 10 mg capsules) act similarly in the body of healthy participants.
About the study drug: Palovarotene is a medication already commercialized by IPSEN, a global biopharmaceutical company. It is used for the treatment of fibrodysplasia ossificans progressiva, a rare, severely disabling condition that causes abnormal bone formation in place of soft and connective tissue, such as ligaments, tendons, and skeletal muscles.
For more information, contact our recruiters at 844-246-8459 or email us at recruitment@biotrial.us
Share this study:
Complete the registration form and call us at 844-246-8459. Our recruiters will be happy to help you, and it will take 5 minutes of your time to know if you are eligible. Your information will be kept strictly confidential.